Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.
about
Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendationsHistological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infectionExacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B.Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study.De novo acute hepatitis B in myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-related microscopic polyangiitis treated with corticosteroids.TNFα-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome c release.Small-molecule inhibitors of the interaction between TNF and TNFR.Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsCurrent hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugsHepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management.Hepatitis B screening before chemotherapy: a survey of practitioners' knowledge, beliefs, and screening practices.Development of novel drug delivery systems using phage display technology for clinical application of protein drugsViral infection and reactivation in autoimmune disease.Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier.Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies.Sustained seroconversion of chronic hepatitis B infection after stem cell transplantation.Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case.Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy.Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis.Clinical significance of chronic hepatitis B virus infection in patients with primary Sjögren's syndrome.Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer.Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain.Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience.Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone.Hepatitis B reactivation after thalidomide.Prophylactic effect of lamivudine on chemotherapy-induced hepatitis B virus reactivation in patients with solid tumour: A meta-analysis.Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis.A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
P2860
Q26784247-B897D824-E6D3-40C2-BCA9-306B55A360BAQ27488374-FCBA6F06-056F-4AFA-95DC-3CF08EFFB831Q33386327-C8495F93-6F4C-4362-90F2-DB783800CD03Q33418708-0EA3BD9E-6B2E-4E6E-B5EB-6D75374CDD4FQ33628268-2E343498-9EB3-4A04-80BA-D0138F6020F0Q34170764-5108D2E9-F7D5-434A-BD17-CB3227C8EF99Q34519187-33DAB2B4-1896-4BF2-BC0F-492E5A947662Q34854165-185C19A1-B6D9-4723-8233-A24D88965D86Q34974883-521109FA-934D-4195-8BCF-BF1841D6AE33Q35610251-D47A1543-D6D0-4A7A-81FC-99ECBBAF0355Q36245362-1A0CE71B-AA8D-4AE3-94E7-9478A0F85400Q36406054-A69362A2-026D-4E1B-987B-E8F28A642E0CQ37198453-088A6DB6-A577-4942-8B92-582B07CCDB53Q37281054-FC8D8741-8D30-4417-B7C6-6BC2F931C911Q37912229-53D81630-B21F-40AE-B398-8426469FC69AQ38714957-1B037741-21B2-4B94-8657-7AC71275D100Q39882778-C009EDBD-71C9-4E5C-8815-B0165F76457BQ40951867-1E26641A-BA05-44FC-9201-2C8F437493EFQ42234350-00DC4788-5D0E-43F1-BDB8-C99942E29F7BQ42952349-8594E7DC-955C-417C-94EA-6D6CC7DB9428Q43480193-717729F3-AEEC-4556-A835-054571AE98B3Q44688947-CE6DC950-CD21-4A76-A8BD-B28B47568B69Q45356997-C3C193B5-92A9-4EBF-B0EA-4F9E4429445EQ45364479-43D80970-9441-4738-8A85-0BBEBC647F55Q45364481-D7B95F41-4BE3-43CD-9C74-454D87211685Q45374247-36F082DC-A83B-4A20-BC83-614FE5465E73Q45382075-C022914B-30CF-4E94-BEBE-CC20B92CDE5DQ45388537-9B3623CA-2D76-4862-A2E0-D3223AA1F06DQ45941147-96B1AD75-73A5-4317-A98D-97DE31E15FB1Q46670706-98332D98-9C7A-43B5-B2BB-A42A260E62A6Q47562286-7ADC9576-4E6E-4464-A67A-F7BDBBD8DDE8Q52362617-41307C0A-8481-40F9-916E-68E7CCCB0822Q58699463-E26FDDAC-B47A-4E00-826B-7F9158AD27AB
P2860
Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Hepatitis B virus reactivation ...... for prevention and management.
@en
type
label
Hepatitis B virus reactivation ...... for prevention and management.
@en
prefLabel
Hepatitis B virus reactivation ...... for prevention and management.
@en
P2860
P1476
Hepatitis B virus reactivation ...... for prevention and management
@en
P2093
P2860
P304
P356
10.1111/J.1445-5994.2007.01479.X
P577
2007-10-01T00:00:00Z